Choose the health content that’s right for you, and get it delivered right in your inbox.
On August 16 and 17, the Florida Hospital Cancer Institute (FHCI) held its third annual Clinical Research Pipeline Meeting and Networking event. This forum engaged our investigators and research team with 20 industry scientific partners to review new compounds being researched and developed. The interaction and discussion at this event each year enable us to secure novel therapies in early phases of development, and the process provides a solid research foundation to provide therapeutic options, including the most current cutting-edge therapies.
There are on average, close to 40 proposed new trials under thorough review for potential study activation. Many of these trials came to fruition at FHCI as a direct result of our discussions with scientific leaders who presented at our Clinical Research Pipeline Meeting.
FHCIs clinical research program maintains a robust menu of approximately 30 studies across all disease sites for adult malignancies and 25 studies in the pediatric setting.
Principal Investigator Update
The FHCI centralized clinical research office continually updates its system to ensure that new studies are activated in a timely manner. Working with our Office of Sponsored Programs (OSP), each step is logged to track and monitor our activation timeline.
A new FHCI requirement for institutional clearance of a new trial is the completion of a coverage analysis. This is the process of determining and documenting the appropriate payor for items and services provided to a subject in a clinical trial. The performance of a coverage analysis is a best practice at leading research institutions to ensure billing compliance. Our FHCI principal investigators are now required to review and sign off on the completed coverage analysis document to initiate the next step of institutional clearance.
Please contact our Clinical Trials Office at 407-303-2090 or email firstname.lastname@example.org for additional information about any of our FHCI clinical research studies.